Ocular Safety Evaluation of Bemarituzumab in FGFR2b-Overexpressing Gastroesophageal Adenocarcinoma: A 42-Week Follow-Up Study
The ocular AEs occurred frequently in patients receiving bemarituzumab, requiring close ophthalmic monitoring and prophylactic administration of FGF-based eye drops. Collaboration between oncologists and ophthalmologists is critical for the timely management of treatment-related AEs, which could ultimately improve overall clinical outcomes.
Authors
- Yanhua Qi (ORCID: https://orcid.org/0000-0002-6234-5317)
- Y. Zhang (ORCID: https://orcid.org/0009-0000-1308-159X)
- Nan Zhou (ORCID: https://orcid.org/0000-0002-2175-2434)
- Jingjie Zhang (ORCID: https://orcid.org/0000-0002-9606-7335)
- Yao Fu
- Fangqi Liu (ORCID: https://orcid.org/0000-0002-3881-5825)
- Gege Tang
Institutions
- Harbin Medical University (CN)
- Second Affiliated Hospital of Harbin Medical University (CN)
Publication Details
- Journal
- Ocular Immunology and Inflammation
- Published
- 2025-12-13
- DOI
- https://doi.org/10.1080/09273948.2025.2603496
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00